| 1563GCC | Mitigation of radiation pneumonitis and fibrosis | Open (affiliates only) |
| 1950GCCC | 1950GCCC: First in Human Phase 1A (dose escalation) and I B (expansion cohorts) Study of [IND # Agent-AG01 a Chimeric Monoclonal Antibody against Glycoprotein GP88] in advanced Solid Tumor Malignancies (1A) with expansion cohorts (1B) in advanced Triple Negative Breast Cancer, Hormone Resistant Breast Cancer, advanced Non-small Cell Lung Cancer (NSCLCA) and advanced Mesothelioma | Open |
| 2221GCCC | A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193
alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors | Open |
| 2230GCCC | BT012:A randomized pivotal study assessing the efficacy of targeted blood-brain barrier (BBB) disruption using Exablate focused ultrasound during the standard of care treatment of brain metastases of non-small cell lung cancer (NSCLC) origin | Open |
| 2261GCCC | 2261GCCC: A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC 9) | Open |
| 2363GCCC | 2363GCCC:Plasma Biomarkers for Lung Cancer Diagnosis (HP-00106262) | Open |
| A081801 | A081801 Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO | Open (affiliates only) |
| NRG-CC009 | Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant
Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
| Open |